Navigation Links
Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
Date:5/24/2010

BEIJING, May 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the 2010 UBS Global Specialty Pharmaceuticals Conference, which is being held June 2-3, 2010 in London, England. Sinovac's presentation is scheduled for Wednesday, June 2, 2010 at 10 a.m. BST/5 a.m. Eastern Time.

A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu (TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more information, please contact:

     Chris Lee
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9659
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/ Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Unaudited First Quarter 2010 Financial Results
2. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
3. Sinovac Announces Upsizing and Pricing of Common Share Offering
4. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
5. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
6. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
7. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
8. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
9. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
10. Sinovac to Present at 2009 UBS Global Life Sciences Conference
11. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):